Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo

Amidon, 1982, Theoretical and experimental studies of transport of micelle-solubilized solutes, J. Pharm. Sci., 71, 77, 10.1002/jps.2600710120

Ano, 2004, Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability, Bioorg. Med. Chem., 12, 257, 10.1016/j.bmc.2003.10.002

Bermejo, 2004, PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones, Eur. J. Pharm. Sci., 21, 429, 10.1016/j.ejps.2003.10.009

Boudreaux, 1993, Use of water-soluble liquid Vitamin E to enhance cyclosporine absorption in children after liver transplant, Transplant. Proc., 25, 1875

Chang, 1996, The effect of water-soluble Vitamin E on cyclosporine pharmacokinetics in healthy volunteers, Clin. Pharmacol. Ther., 59, 297, 10.1016/S0009-9236(96)80007-5

Collett, 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2, J. Pharmacol. Exp. Ther., 288, 171

Dhanikula, 1999, Localized paclitaxel delivery, Int. J. Pharm., 183, 85, 10.1016/S0378-5173(99)00087-3

Dintaman, 1999, Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), Pharm. Res., 16, 1550, 10.1023/A:1015000503629

Fagerholm, 1996, Comparison between permeability coefficients in rat and human jejunum, Pharm. Res., 13, 1336, 10.1023/A:1016065715308

Feng, 2004, Nanoparticles of biodegradable polymers for clinical administration of paclitaxel, Curr. Med. Chem., 11, 413, 10.2174/0929867043455909

Hanafy, 2001, Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats, Eur. J. Pharm. Sci., 12, 405, 10.1016/S0928-0987(00)00195-0

Ismailos, 1994, Enhancement of cyclosporin A solubility by d-alpha-tocopheryl-polyethylene-glycol-1000 succinate (TPGS), Eur. J. Pharm. Sci., 1, 269, 10.1016/0928-0987(94)90021-3

Joshi, R., Sands, H., Rubinfeld, J., 2003. Methods for administration of paclitaxel. US Patent 6,828,346, to SuperGen, Inc., Dubin, CA.

Kansy, 1998, Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes, J. Med. Chem., 41, 1007, 10.1021/jm970530e

Kaus, 1999, The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities, Pharm. Res., 16, 272, 10.1023/A:1018836727001

Kimura, 2002, P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel, Cancer Chemother. Pharmacol., 49, 322, 10.1007/s00280-001-0419-x

Malingre, 2001, Oral delivery of taxanes, Invest. New Drug., 19, 155, 10.1023/A:1010635000879

Mouly, 2003, P-glycoprotein increases from proximal to distal regions of human small intestine, Pharm. Res., 20, 1595, 10.1023/A:1026183200740

Mu, 2003, A novel controlled release formulation for the anticancer drug aclitaxel (Taxol): PLGA nanoparticles containing Vitamin E TPGS, J. Control Release, 86, 3, 10.1016/S0168-3659(02)00320-6

Nerurkar, 1997, Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells, J. Pharm. Sci., 86, 813, 10.1021/js960483y

Panchagnula, 1998, Pharmaceutical aspects of paclitaxel, Int. J. Pharm., 172, 1, 10.1016/S0378-5173(98)00188-4

Rege, 2002, Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers, Eur. J. Pharm. Sci., 16, 237, 10.1016/S0928-0987(02)00055-6

Siegmund, 2003, Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets, J. Pharm. Sci., 92, 604, 10.1002/jps.10327

Sokol, 1991, Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble Vitamin E, Lancet, 338, 212, 10.1016/0140-6736(91)90349-T

Sparreboom, 1997, Limited oral bioavailability and active epithelial exertion of paclitaxel (Taxol) caued by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. U.S.A., 94, 2031, 10.1073/pnas.94.5.2031

Stephens, 2001, Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia, J. Pharmacol. Exp. Ther., 296, 584

Stephens, 2002, Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a(−/−) mice, Br. J. Pharmacol., 135, 2038, 10.1038/sj.bjp.0704668

Troutman, 2003, Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium, Pharm. Res., 20, 1210, 10.1023/A:1025001131513

van Asperen, 1997, Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 8333, Br. J. Cancer, 76, 1181, 10.1038/bjc.1997.530

van Asperen, 1998, Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A, Clin. Cancer Res., 4, 2293

Varma, 2003, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharmacol. Res., 48, 347, 10.1016/S1043-6618(03)00158-0

Varma, 2004, Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research, Curr. Drug Metab., 5, 375, 10.2174/1389200043335423

Varma, 2005, Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein-mediated efflux transport, Mol. Pharm., 2, 12, 10.1021/mp0499196

Varma, 2005, pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs. 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples, J. Chromatogr. B, 816, 243, 10.1016/j.jchromb.2004.11.040

Varma, M.V.S., Panchagnula, R., 2005. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J. Pharm. Sci., in press.

Wacher, 2002, Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by d-alpha-tocopheryl poly(ethylene glycol 1000) succinate, J. Pharmacol. Exp. Ther., 303, 308, 10.1124/jpet.102.036541

Williams, 1999, Oral absorption of the HIV protease inhibitors: a current update, Adv. Drug Delivery Rev., 39, 211, 10.1016/S0169-409X(99)00027-7

Win, 2005, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer dugs, Biomaterials, 26, 2713, 10.1016/j.biomaterials.2004.07.050

Woo, 2003, Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031, Pharm. Res., 20, 24, 10.1023/A:1022286422439

Yamazaki, 2001, In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and permeability of in vivo results, J. Pharmacol. Exp. Ther., 296, 723

Yang, 2004, Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors, Pharm. Res., 21, 261, 10.1023/B:PHAM.0000016238.44452.f1

Yu, 1999, Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, Pharm. Res., 16, 1812, 10.1023/A:1018939006780

Zhang, 2000, Studies on the cyclosporin A loaded stearic acid nanoparticles, Int. J. Pharm., 200, 153, 10.1016/S0378-5173(00)00361-6